A nanomaterial targeting the spike protein captures SARS-CoV-2 variants and promotes viral elimination

While vaccines have curbed the COVID-19 pandemic, effective therapeutic treatments are few, and might be challenged by SARS-CoV-2 variants. A biocompatible, antiviral two-dimensional nanomaterial is now reported that firmly adsorbs the virus by interaction with the spike protein, inducing the conformational changes that lead to inhibition of viral infection in vitro and in animal models. The global emergency caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic can only be solved with effective and widespread preventive and therapeutic strategies, and both are still insufficient. Here, we describe an ultrathin two-dimensional CuInP2S6 (CIPS) nanosheet as a new agent against SARS-CoV-2 infection. CIPS exhibits an extremely high and selective binding capacity (dissociation constant (K-D) < 1 pM) for the receptor binding domain of the spike protein of wild-type SARS-CoV-2 and its variants of concern, including Delta and Omicron, inhibiting virus entry and infection in angiotensin converting enzyme 2 (ACE2)-bearing cells, human airway epithelial organoids and human ACE2-transgenic mice. On association with CIPS, the virus is quickly phagocytosed and eliminated by macrophages, suggesting that CIPS could be successfully used to capture and facilitate virus elimination by the host. Thus, we propose CIPS as a promising nanodrug for future safe and effective anti-SARS-CoV-2 therapy, and as a decontamination agent and surface-coating material to reduce SARS-CoV-2 infectivity.

Automated summary

A biocompatible and antiviral two-dimensional nanomaterial has been reported, which can firmly adsorb the virus and inhibit viral infection through conformational changes induced by interaction with the spike protein. This study proposes CIPS as a promising nanodrug for future anti-SARS-CoV-2 therapy, and also as a decontamination agent and surface-coating material to reduce SARS-CoV-2 infectivity.